The combination of sodium valproate and sodium dichloroacetate, as well as temozolomide, had individual impacts in vitro on the SLC12A2, SLC12A5, CDH1, CDH2, EZH, and GFAP expressions in GBM5-1, GBM5-2F, and GBM5-3F primary cells of GBM wild-type tumors. The gene discussed is CDH2; the disease is glioblastoma.